Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Tryptamine Therapeutics ( (AU:TYP) ) has issued an update.
Tryptamine Therapeutics Limited announced the resignation of Mark Davies as a director, effective May 12, 2025. This change in leadership is accompanied by a disclosure of Davies’ interests in the company’s securities, including various unlisted director options and ordinary fully paid shares. The departure of a director may impact the company’s strategic direction and stakeholder confidence, particularly given Davies’ significant holdings and involvement with the company.
More about Tryptamine Therapeutics
Tryptamine Therapeutics Limited operates in the pharmaceutical industry, focusing on the development of innovative therapeutic solutions. The company is involved in the research and production of treatments that aim to address various health conditions, with a particular emphasis on advancing mental health therapies.
Average Trading Volume: 1,751,616
Technical Sentiment Signal: Buy
Current Market Cap: A$50.36M
See more data about TYP stock on TipRanks’ Stock Analysis page.